Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

被引：5
|
作者：
Brannigan, Jamie [1 ]
Jones, Joanne L. [2 ]
Stacpoole, Sybil R. L. [1 ,2 ,3 ]
机构：
[1] Univ Cambridge, Jesus Coll, Cambridge CB2 1TN, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England
[3] North West Anglia NHS Fdn Trust, Peterborough City Hosp, Dept Neurol, Peterborough, Cambs, England
来源：
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2020年 / 7卷 / 05期
基金：
英国惠康基金;
关键词：
D O I：
10.1212/NXI.0000000000000799
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Alemtuzumab as Treatment for Multiple Sclerosis
    Katsavos, Serafeim
    Coles, Alasdair
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (10):
  • [22] Case series of three patients with multiple sclerosis showing severe activation of disease during immunotherapy with alemtuzumab
    Wehrum, T.
    Beume, L. A.
    Mader, I.
    Maeurer, M.
    Czaplinski, A.
    Weiller, C.
    Stich, O.
    Rauer, S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 862 - 862
  • [23] Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis
    Adamec, Ivan
    Habek, Mario
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (05) : 139 - 141
  • [24] Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease
    Alcala, Carmen
    Pzere-Miralles, F.
    Gasc, F.
    On Evole, M.
    Estutia, M.
    Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 27 : 406 - 408
  • [25] Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis
    Wehrum, Thomas
    Beume, Lena-Alexandra
    Stich, Oliver
    Mader, Irina
    Maeurer, Mathias
    Czaplinski, Adam
    Weiller, Cornelius
    Rauer, Sebastian
    NEUROLOGY, 2018, 90 (07) : E601 - E605
  • [26] Fatal bilateral intracerebral hemorrhage following treatment with alemtuzumab for multiple sclerosis
    Sinicina, I.
    Schlegel, J.
    Bise, K.
    Liesche, F.
    Pankratz, H.
    RECHTSMEDIZIN, 2019, 29 (02) : 129 - 132
  • [27] Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis
    Pappolla, Agustin
    Midaglia, Luciana
    Boix Rodriguez, Claudia P.
    Albasanz Puig, Adaia
    Lung, Maiylyi
    Ruiz Camps, Isabel
    Castillo, Joaquin
    Mulero, Patricia
    Vidal-Jordana, Angela
    Arrambide, Georgina
    Rodriguez-Acevedo, Breogan
    Sastre-Garriga, Jaume
    Rio, Jordi
    Comabella, Manuel
    Galan, Ingrid
    Tintore, Mar
    Montalban, Xavier
    NEUROLOGY, 2019, 92 (06) : 296 - 298
  • [28] Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report
    Romero, A.
    Midaglia, L.
    Salcedo, M. T.
    Viladomiu, L.
    Guillen, E.
    Bajana, I
    Escola-Verge, L.
    Tintore, M.
    Montalban, X.
    Len, O.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 40
  • [29] Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis
    Hyun, Jae-Won
    Kim, Yeseul
    Kim, Gayoung
    Kim, Su-Hyun
    Kim, Ho Jin
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (14) : 1942 - 1945
  • [30] A case of fulminant Goodpasture syndrome following alemtuzumab treatment for multiple sclerosis
    Lapointe, E.
    Moghaddam, B.
    Barclay, K.
    Neufeld, P.
    Phelps, R.
    Traboulsee, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 640 - 640
12345